CD19 CAR-T cells
CD19 CAR-T cells is a biological therapy with 14 clinical trials. Currently 8 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
11
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
8
trials recruiting
14
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
A Multicenter Study of CAR-T Cells in Primary Ph+All
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Clinical Trials (14)
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
A Multicenter Study of CAR-T Cells in Primary Ph+All
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
All 14 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 14